Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
NCT07174583 · View on ClinicalTrials.gov ↗
Study Summary
This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.
Conditions Studied
Interventions
- DRUG IDE849
- DRUG durvalumab
- DRUG IDE161
Study Locations (20)
Texas
- The University of Texas MD Anderson Cancer Center Houston, Texas 77030-4000 — Houston
- Oncology Consultants, PA - Houston — Houston
- Next Oncology Dallas — Irving
Florida
- Mayo Clinic Hospital - Florida — Jacksonville
- Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando
Illinois
- The University of Chicago Medical Center - Duchossois Center for Advanced Medicine — Chicago
- OSF HealthCare Cancer Institute — Peoria
Michigan
- Trinity Health-IHA Medical Group - Hematology Oncology - Ann Arbor Campus — Ann Arbor
- The Cancer and Hematology Centers — Grand Rapids
New York
- Columbia University Medical Center - Herbert Irving Pavilion — New York
- Weill Cornell Medicine - Cutaneous Oncology and Melanoma Program — New York
Washington
- Swedish Cancer Institute — Seattle
- Seattle Cancer Care Alliance — Seattle
Colorado
- Sarah Cannon Research Institute at HealthONE — Denver
Georgia
- Piedmont Physicians Medical Oncology - Atlanta — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2025-10-14 |
| Est. Completion | 2029-05 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07174583
The ClinicalTrials.gov registry entry for NCT07174583 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is IDEAYA Biosciences, which has 36 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions — of which IDE849 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07174583 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Texas, Florida, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07174583 about?
NCT07174583 is a clinical study titled "A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer". This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.
What is the current status of trial NCT07174583?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 208 participants. The study started on 2025-10-14. Estimated completion is 2029-05.
What conditions does trial NCT07174583 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07174583?
The interventions under investigation include: IDE849 (DRUG), durvalumab (DRUG), IDE161 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07174583?
This trial is sponsored by IDEAYA Biosciences, which has 36 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07174583 being conducted?
This trial has 20 study locations across Colorado, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.